The drug developed by Chinese scientists is aimed at solving the main problem of bacterial resistance to existing antibiotics. It is intended for the treatment of complex skin and soft tissue infections caused by bacteria with a high risk of resistance.
It took ten years to create the drug kinomycin. Now the team from the University of Hong Kong has received approval from the Chinese regulator to conduct pilot clinical trials. Kinomycin is a more advanced type of cyclic lipopeptide antibiotic with a new chemical structure, according to the university’s website.
Kinomycin is designed to treat complex skin and soft tissue infections that are very common in clinical practice and often lead to hospitalization and severe complications. The current treatment options for some patients are largely limited due to the growth of bacterial resistance to existing antibiotics. It is expected that kinomycin will increase the effectiveness and safety of treatment.
First of all, kinomycin is considered to be a more effective version of the cyclic lipopeptide antibiotic daptomycin. In preclinical studies, the drug showed improved antimicrobial activity and lower cytotoxicity. Kinomycin has been shown to be effective in killing methicillin-resistant Staphylococcus aureus and a number of other pathogens resistant to daptomycin.
Bacterial resistance to antibiotics is considered one of the main threats to human health. Recently, scientists have conducted research and found out the evolutionary causes of resistance.
